Instrument Inactif

Communiqués Merrimack Pharmaceuticals Inc Nasdaq

Actions

US5903281005

Recherche biotechnologique et médicale

Communiqués

13/05/24	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution and Cash Liquidating Dividend Amount of $15.10 per Share of Common Stock	AQ
10/05/24	Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock	BU
09/05/24	Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution	BU
30/04/24	Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution	BU
27/03/24	Merrimack Receives $225 Million Milestone Payment from Ipsen	BU
07/03/24	Merrimack Reports Full Year 2023 Financial Results	BU
14/02/24	Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma	AQ
13/02/24	Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)	BU
02/11/23	Merrimack Reports Third Quarter 2023 Financial Results	BU
03/08/23	Merrimack Reports Second Quarter 2023 Financial Results	BU
04/05/23	MERRIMACK PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
04/05/23	Merrimack Reports First Quarter 2023 Financial Results	BU
04/05/23	MERRIMACK PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
09/03/23	MERRIMACK PHARMACEUTICALS INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
09/03/23	Merrimack Reports Full Year 2022 Financial Results	BU
09/03/23	MERRIMACK PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
05/12/22	MERRIMACK PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Regulation FD Disclosure (form 8-K)	AQ
05/12/22	Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan	BU
10/11/22	Merrimack Provides Ipsen Report That Onivyde Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma	AQ
09/11/22	MERRIMACK PHARMACEUTICALS INC : Regulation FD Disclosure, Other Events (form 8-K)	AQ
03/11/22	Merrimack Reports Third Quarter 2022 Financial Results	BU
03/11/22	MERRIMACK PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)	AQ
03/11/22	MERRIMACK PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
04/08/22	Merrimack Pharmaceuticals : Reports Second Quarter 2022 Financial Results - Form 8-K	PU
04/08/22	Merrimack Reports Second Quarter 2022 Financial Results	BU